FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022647553> ?p ?o ?g. }

• W3022647553 abstract "Background: We aimed to explore whether the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes and adverse events for HER2-positive breast cancer patients receiving neoadjuvant therapy (NAT). Methods: A total of 65 HER2-positive breast cancer patients receiving NAT were analyzed. The concentration of serum miR-222-3p was detected by quantitative real-time PCR. Logistic regression analysis was used to identify the association of serum miR-222-3p with pathological complete response (pCR). The relationship of serum miR-222-3p with disease-free survival (DFS) and overall survival (OS) was examined via log-rank test and Cox proportional hazards analysis. The ordered logistic regression was applied to evaluate the association between serum miR-222-3p and adverse events. Results: The miR-222-3p low group was more likely to achieve pCR [odds ratio (OR) = 0.258, P = 0.043]. The interaction between miR-222-3p and presenting Ki67 level was also detected for pCR (OR=49.230, Pinteraction = 0.025). The miR-222-3p low group was correlated with superior DFS (P = 0.029) and OS (P = 0.0037). The expression of serum miR-222-3p was the independent protective factor for trastuzumab-induced cardiotoxicity (P < 0.05) and anemia (P = 0.013). Conclusions: Serum miR-222-3p is the potential factor to predict pCR, survival benefit and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving NAT." @default.
• W3022647553 created "2020-05-13" @default.
• W3022647553 creator A5003642180 @default.
• W3022647553 creator A5004853365 @default.
• W3022647553 creator A5006099817 @default.
• W3022647553 creator A5006422020 @default.
• W3022647553 creator A5024572557 @default.
• W3022647553 creator A5035480324 @default.
• W3022647553 creator A5041617519 @default.
• W3022647553 creator A5044108333 @default.
• W3022647553 creator A5057497297 @default.
• W3022647553 creator A5067790992 @default.
• W3022647553 creator A5073501391 @default.
• W3022647553 creator A5074615872 @default.
• W3022647553 creator A5082102216 @default.
• W3022647553 creator A5088039838 @default.
• W3022647553 date "2020-04-28" @default.
• W3022647553 modified "2023-10-17" @default.
• W3022647553 title "Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy" @default.
• W3022647553 cites W1530219086 @default.
• W3022647553 cites W1602041588 @default.
• W3022647553 cites W1759409403 @default.
• W3022647553 cites W1807268679 @default.
• W3022647553 cites W1971831531 @default.
• W3022647553 cites W1987326983 @default.
• W3022647553 cites W1992234802 @default.
• W3022647553 cites W1999507007 @default.
• W3022647553 cites W2005311581 @default.
• W3022647553 cites W2006070721 @default.
• W3022647553 cites W2014166418 @default.
• W3022647553 cites W2017857120 @default.
• W3022647553 cites W2020372547 @default.
• W3022647553 cites W2028492986 @default.
• W3022647553 cites W2029542561 @default.
• W3022647553 cites W2030701238 @default.
• W3022647553 cites W2040651420 @default.
• W3022647553 cites W2043958752 @default.
• W3022647553 cites W2057650091 @default.
• W3022647553 cites W2059411043 @default.
• W3022647553 cites W2068326740 @default.
• W3022647553 cites W2069588389 @default.
• W3022647553 cites W2086805204 @default.
• W3022647553 cites W2087206434 @default.
• W3022647553 cites W2090570877 @default.
• W3022647553 cites W2093870248 @default.
• W3022647553 cites W2096910745 @default.
• W3022647553 cites W2097960989 @default.
• W3022647553 cites W2100271152 @default.
• W3022647553 cites W2104337757 @default.
• W3022647553 cites W2105436256 @default.
• W3022647553 cites W2107501691 @default.
• W3022647553 cites W2107831804 @default.
• W3022647553 cites W2115093090 @default.
• W3022647553 cites W2119693744 @default.
• W3022647553 cites W2121915946 @default.
• W3022647553 cites W2144621400 @default.
• W3022647553 cites W2150322923 @default.
• W3022647553 cites W2151262170 @default.
• W3022647553 cites W2152194768 @default.
• W3022647553 cites W2180644401 @default.
• W3022647553 cites W2278684016 @default.
• W3022647553 cites W2318605753 @default.
• W3022647553 cites W2345920029 @default.
• W3022647553 cites W2461221680 @default.
• W3022647553 cites W2508255574 @default.
• W3022647553 cites W2513350637 @default.
• W3022647553 cites W2519885213 @default.
• W3022647553 cites W2524552969 @default.
• W3022647553 cites W2532189621 @default.
• W3022647553 cites W2533849096 @default.
• W3022647553 cites W2563174005 @default.
• W3022647553 cites W2563670936 @default.
• W3022647553 cites W2588757737 @default.
• W3022647553 cites W2594664085 @default.
• W3022647553 cites W2601621556 @default.
• W3022647553 cites W2606611953 @default.
• W3022647553 cites W2625859437 @default.
• W3022647553 cites W2737829281 @default.
• W3022647553 cites W2758187157 @default.
• W3022647553 cites W2770090035 @default.
• W3022647553 cites W2774580734 @default.
• W3022647553 cites W2792566138 @default.
• W3022647553 cites W2800389271 @default.
• W3022647553 cites W2807055401 @default.
• W3022647553 cites W2883114613 @default.
• W3022647553 cites W2883208697 @default.
• W3022647553 cites W2884883121 @default.
• W3022647553 cites W2886922919 @default.
• W3022647553 cites W2889539710 @default.
• W3022647553 cites W2903447346 @default.
• W3022647553 cites W2905407753 @default.
• W3022647553 cites W2908847665 @default.
• W3022647553 cites W2910837626 @default.
• W3022647553 cites W2911225106 @default.
• W3022647553 cites W2912418307 @default.
• W3022647553 cites W2915058250 @default.
• W3022647553 cites W2935852942 @default.
• W3022647553 cites W2942862617 @default.
• W3022647553 cites W2966630047 @default.
• W3022647553 cites W2986933370 @default.

• next